European Medicines Agency

The European Medicines Agency plays an important role in protecting the health of all European Union (EU) citizens, including older people.
The number of people aged 65 years or over in the EU is expected to grow from around 84 million in 2008 to around 141 million by 2050. As the older population grows, the Agency recognises that it will need to make sure that it takes the needs of the elderly into account during the development, approval and use of medicines.
The Agency engages with regulatory authorities, pharmaceutical companies and organisations representing the interests of elderly people in Europe and beyond, including with patient, consumer and healthcare professional organizations.
Read more:

European Union Geriatric Medicine Society

In 1999 a group of European geriatricians met to promote the concept of a scientific society whose aim would be to develop geriatric medicine in all of the European Union countries and encourage the provision of geriatric medical services to all older EU citizens. EUGMS promotes education, continuing professional development and high quality evidence-based geriatric medicine.
Read more:

The European Federation of Pharmaceutical Industries and Associations (EFPIA)

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Read more:

The Innovative Medicines Initiative (IMI):

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organizations, and medicines regulators. IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Read more:

National Institute on Aging (NIA):

NIA, one of the 27 Institutes and Centers of National Institute of Health, leads the federal government in conducting and supporting research on aging and the health and well-being of older people. The Institute seeks to understand the nature of aging and the aging process, and diseases and conditions associated with growing older, in order to extend the healthy, active years of life.
Read more:



Italia Longeva:

Italy is one of the oldest countries of the world. Moreover, 2012 was the European Year for Active Ageing and Solidarity between Generations. For these reasons, Italia Longeva, the Italian network dedicated to aging, was created by the Ministry of Health, by the Marche Region and by the IRCCS INRCA to promote a new vision of the older person as a resource for the society, i.e. a healthy, active and engaged citizen, rich of experience and wisdom. The older person is also a consumer of goods, that need to be invented, and of services, which should be reinvented. The older person should be at the center of a country that offers opportunities for economic and social development, that stimulates research and innovation and promotes the implementation of new technologies. This is the program that Italia Longeva wants to launch nationwide, starting from the Marche Region, in order to improve the quality of life of older persons, make them as independent as possible, reduce the consumption of drugs, and eventually reduce the costs of the National Health Service.
Read more: is an international educational website that aims to help geriatricians, primary care physicians and other health care professionals involved in the care of older persons to implement frailty management into clinical practice. This educational website is endorsed by the International Association of Gerontology and Geriatrics (IAGG) and its Global Aging Research Network (GARN), and it is supported by The Journal of Frailty & Aging (JFA).
Read more:

SarcopeniaOnLine: The Italian Portal on Sarcopenia & Nutrition:

The aim of SarcopeniaOnLine is to improve knowledge concerning sarcopenia and nutrition, with particular reference to the diagnosis and treatment. In the portal relevant information on sarcopenia, on its diagnosis and possible therapeutic interventions will be provided, together with the latest publications related to sarcopenia and nutrition. SarcopeniaOnLine will provide the access to a number of useful tools for the assessment of nutritional status and muscle strength and will inform on the events dedicated to this theme.
SarcopeniaOnLine content is provided by the Italian Working Group Sarcopenia - Treatment and Nutrition (Glisten Group), which operates as a study group of the Italian Society of Geriatrics and Gerontology.
Read more:

Canadian Frailty Network:

Canadian Frailty Network (CFN) is Canada’s network for frail older adults. It supports original research, and train the next generation of health care professionals and scientists to improve outcomes for older Canadians across all settings of care. Recognizing they may be nearing the end of life, CFN is dedicated to improving advance care planning and end-of-life care.
Canadian Frailty Network is funded by the Government of Canada’s Networks of Centres of Excellence (NCE) program. The NCE program’s goal is to mobilize collaborations between researchers, industry and other organizations to produce programs and products that further Canada’s economic strength and improve the quality of life of Canadians.
Read more: